Skip to main content
Merrill Biel, MD, Otolaryngology (ENT), Minneapolis, MN, Regina Hospital

MerrillA.BielMDPhD FACS

Otolaryngology (ENT) Minneapolis, MN

Head & Neck Microvascular Surgery, Head & Neck Oncologic Surgery, Laryngology & Voice Disorders

Professor, Otolaryngology, University of Minnesota Medical School

Dr. Biel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Biel's full profile

Already have an account?

Education & Training

  • University of Minnesota
    University of MinnesotaResidency, Otolaryngology - Head and Neck Surgery, 1983 - 1987
  • Hennepin Healthcare
    Hennepin HealthcareResidency, Surgery, 1982 - 1983
  • University of Minnesota
    University of MinnesotaInternship, Internal Medicine, 1981 - 1982
  • University of Illinois College of Medicine
    University of Illinois College of MedicineClass of 1981

Certifications & Licensure

  • MN State Medical License
    MN State Medical License 1983 - 2024
  • American Board of Otolaryngology - Head and Neck Surgery Otolaryngology

Awards, Honors, & Recognition

  • Super Doctor SuperDoctors.com
  • Fellow (FACS) American College of Surgeons
  • Top MD Consumers Checkbook
  • Join now to see all

Publications & Presentations

PubMed

Lectures

  • A global phase III multicenter, randomized, double-arm, open label trial of ASP-1929 photoimmunotherapy versus physician’s choice standard of care for the treatment of... 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019

Press Mentions

  • Rakuten Aspyrian Enrolling Phase 3 Trial of ASP-1929 for Head and Neck Cancer
    Rakuten Aspyrian Enrolling Phase 3 Trial of ASP-1929 for Head and Neck CancerDecember 17th, 2018
  • Aspyrian Therapeutics Inc. Announces Successful Advances in RM-1929 Clinical Development in Recurrent Head and Neck Cancer, Including Fast Track Designation Granted by the FDA, Initiation of Clinical Studies in Japan, and Plans to Start Pivotal Studies, W
    Aspyrian Therapeutics Inc. Announces Successful Advances in RM-1929 Clinical Development in Recurrent Head and Neck Cancer, Including Fast Track Designation Granted by the FDA, Initiation of Clinical Studies in Japan, and Plans to Start Pivotal Studies, WJanuary 16th, 2018

Grant Support

  • Photodynamic Treatment Of Endotracheal Tube BiofilmsNational Institute Of Allergy And Infectious Diseases2005–2007
  • Antimicrobial Chronic Wound Bandage TreatmentNational Institute Of Nursing Research2004–2006
  • Treatment Of Aids-Related Oral CandidiasisNational Institute Of Dental &Craniofacial Research2002–2004
  • Phototherapy Of Antibiotic Resistant Wound InfectionsNational Institute Of Allergy And Infectious Diseases2000

Professional Memberships

Hospital Affiliations